Interleukin-6 Gene Expression Changes after a 4-Week Intake of a Multispecies Probiotic in Major Depressive...

Area of Science:

• Neuroscience
• Immunology
• Microbiology

Background:

• Major depressive disorder (MDD) affects many individuals, with a significant portion unresponsive to conventional antidepressant therapies.
• Probiotics offer a potential avenue for well-tolerated and cost-effective treatments for MDD, though their precise molecular mechanisms require further elucidation.
• Emerging evidence suggests probiotics may positively modulate inflammatory pathways, which are implicated in the pathophysiology of depression.

Purpose of the Study:

• To investigate the effects of a multispecies probiotic intervention on the gene expression of key inflammation markers in patients with MDD.
• To analyze changes in tumor necrosis factor (TNF), nuclear factor kappa B subunit 1 (NFKB1), and interleukin-6 (IL-6) gene expression.

Main Methods:

• A randomized, placebo-controlled trial (PROVIT study) involving 61 inpatients diagnosed with MDD.
• Fasting blood samples were collected before and after a four-week intervention period.
• Gene expression analysis was performed for TNF, NFKB1, and IL-6.

Main Results:

• While no significant main effects for group or time were observed for IL-6, a significant interaction effect was found (p < 0.05).
• The probiotic intervention group exhibited a decrease in IL-6 gene expression.
• Conversely, the placebo group showed an increase in IL-6 gene expression over the study period.

Conclusions:

• Probiotics demonstrate potential anti-inflammatory effects relevant to MDD treatment.
• The observed modulation of IL-6 gene expression suggests probiotics could serve as an adjunctive therapy for depression.
• Further research is warranted to fully explore the therapeutic benefits of probiotic interventions in individuals with depression.